Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06253377 Active, not recruiting - Sepsis Clinical Trials

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

Start date: December 8, 2023
Phase:
Study type: Observational

It is an epidemiology study to explore outcomes in patients with acute kidney injury (AKI) and sepsis submitted to continuous renal replacement therapy (CRRT) with Oxiris™. Objectives: Describe the experience and outcomes in patients with sepsis and AKI treated receiving CRRT with the adsorption membrane filter Oxiris™

NCT ID: NCT06211829 Active, not recruiting - Clinical trials for Bacterial Infections

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

Start date: May 18, 2022
Phase:
Study type: Observational

In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday - Friday from 0700 to 1500), a note outlining optimal interventions was written in the electronic medical record (EMR), and the recommendations were communicated to the primary team via secure messaging or telephone

NCT ID: NCT06197828 Active, not recruiting - Sepsis Clinical Trials

Novel Biomarkers for Early Renal Injury in Children With Sepsis

Start date: May 1, 2021
Phase:
Study type: Observational

Toxicosis often leads to multiple organ failure (MODS), with the kidney being the primary target organ due to its sensitivity to infection and ischemia. The kidney's vulnerability makes it a potential early indicator of organ failure, implying that further organ failure may occur later, thereby increasing the risk of patient mortality. Several studies conducted on sepsis patients in the Pediatric Intensive Care Unit (PICU) have revealed that 40.32% of sepsis patients experienced complications with acute kidney injury (AKI), and the case fatality rate could rise to 70% once AKI occurred. The Kidney Disease Improving Global Outcomes (KDIGO) scale is commonly used as a diagnostic criterion for AKI. However, the kidney's robust reserve function poses a challenge for early identification, diagnosis, and intervention of AKI since significant increases in creatinine levels and a sharp decrease in urine volume already indicate severe kidney damage. This situation calls for the development of alternative methods. In our previous study, we discovered a strong correlation between urinary oxygen partial pressure and renal organ function impairment in children with sepsis. Building upon traditional biochemical indicators such as blood lactic acid levels, we will incorporate non-invasive tests like urine partial pressure of oxygen, renal ultrasound, and cardiac ultrasound, as well as novel markers like KIM-1, to establish a model for early recognition and assessment of kidney damage in children with sepsis. By utilizing commonly used biomarkers and the precise effects of urinary oxygen partial pressure, we aim to improve early identification and accurate intervention evaluation for pediatric sepsis kidney injury. This research will provide a crucial foundation for the development of early warning systems, diagnostic guidelines, and treatment protocols for pediatric sepsis kidney injury.

NCT ID: NCT06167083 Active, not recruiting - Clinical trials for Carbapenem Resistant Bacterial Infection

Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)

ICU
Start date: April 12, 2024
Phase:
Study type: Observational

Using our own patient data, our study aimed to predict mortality that can develop in Carbapenem-resistant Gram-negative bacilli bloodstream infections with a machine learning-based model. In the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison.

NCT ID: NCT06126263 Active, not recruiting - Clinical trials for Infection, Bacterial

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

iGASAntitox
Start date: January 1, 2023
Phase:
Study type: Observational

This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS) between the years 2015-2021

NCT ID: NCT06014736 Active, not recruiting - Clinical trials for Staphylococcus Aureus Bloodstream Infection

A Phase I Study of XJ101 in Chinese Healthy Subjects

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

NCT ID: NCT05953675 Active, not recruiting - Clinical trials for Hemodialysis Complication

Ethanol Lock and Risk of Catheter Related Blood Stream Infection in Patients With Haemodialysis Catheter

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to examine the effect of ethanol (70%) as lock-solution after hemodialysis on: - The frequency of dialysis catheter-related bacteremia among patients under observation of potential complications - Other complications of the use of hemodialysis-catheters eg. dysfunction of the catheter due to thrombosis.

NCT ID: NCT05623098 Active, not recruiting - Sepsis Clinical Trials

Effects of Dietary Fiber on Bone Metabolism

Start date: April 1, 2022
Phase:
Study type: Observational

Clinical and animal studies have found that sepsis can lead to a serious imbalance in the gut microecology, a reduction in probiotics, a reduction in short-chain fatty acid, a reduction in bone mass, and an increase in bone destruction, maintaining the stability of microecology can be one of the effective means of bone protection. But at present, the treatment of sepsis with early supplementation of probiotics is still controversial, and dietary fiber intake has significantly changed the composition of the microbiota, it may be a safe and effective method to prevent bone loss in sepsis. Further study on it will provide reliable theoretical basis and intervention target for early, safe and effective prevention of osteoporosis.

NCT ID: NCT05507437 Active, not recruiting - Clinical trials for Acute Kidney Injury Due to Sepsis

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Start date: November 22, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

NCT ID: NCT05485051 Active, not recruiting - Clinical trials for Ventilator Associated Pneumonia

Daily Chlorexidine Bath for Health Care Associated Infection Prevention

CLEAN-IT
Start date: August 3, 2022
Phase: Phase 3
Study type: Interventional

Cluster randomized controlled trial comparing two bathing strategies in critically ill patients. The intervention group will receive daily bathing with chlorhexidine. The control group will receive usual care.